GlobeNewswire

IRIDEOS Acquires Enter

Dela

IRIDEOS Enhances Recent Strategic Acquisitions With Purchase of Leading Italian-Based Network and Cloud Services Provider

MILAN, Italy, June 18, 2018 (GLOBE NEWSWIRE) -- IRIDEOS, the new Italian ICT provider for Businesses and Public Administration, announces today the acquisition of Enter, a leader in network and cloud services based in Italy. This purchase is the most recent of IRIDEOS acquisitions as the company works to consolidate the cloud and data center market throughout Italy.

"With this new acquisition, our growth path continues, focused on strengthening our assets and skills in the Italian ICT space," says  Mauro  Maia, CEO of IRIDEOS. "A wider portfolio of services is now available for our customers, with new cloud solutions and international connectivity."

As a leading ISP focused on providing global network connectivity, Enter's IP backbone spans 35+ Points of Presence (PoPs) worldwide, providing a wide range of network services, including Ethernet, VPN and cloud interconnection. Enter also provides Cloud Infrastructure-as-a-Service (IaaS) solutions, the first European, OpenStack-based service of its kind. This comprehensive solution provides customers with the computing, storage, network, DNS and CDN solutions they require to build an effective cloud solution.

"This is an exciting time for the Italian telecommunications industry as IRIDEOS works to consolidate cloud, network and data center providers throughout the region," shares Ivan Botta, CEO, Enter. "We look forward to joining IRIDEOS as we work together to provide solutions that exceed customer expectations."

As a result of this strategic acquisition, Enter will be part of a wider portfolio of services with a densified fiber footprint and additional colocation opportunities throughout the Italian market and will continue to deliver high-quality cloud and connectivity solutions to users around the globe.

IRIDEOS' purchase of Enter follows the recent acquisitions of Infracom Italia, KPNQwest Italia, MC-link and BiG TLC. As a result of these purchases, the IRIDEOS technological platform now integrates 12 data centers across Milan, Rome, Trento, and Verona, the largest Italian private Internet exchange (Avalon) and 15,000 km of proprietary optical fiber along the major highways.

For more information about IRIDEOS, visit www.irideos.it/en/. To learn more about Enter, visit www.enter.it/en/

About IRIDEOS

IRIDEOS is the new Italian ICT provider for Businesses and Public Administration. 80% owned by F2i SGR and 20% by the European fund Marguerite, IRIDEOS aggregates and consolidates the assets and skills of four Italian operators focused on business customers: Infracom, KPNQWest Italia, MC-link and BiG TLC. IRIDEOS' solutions combine cloud, data center, optical fiber, security and managed services, leveraging a technological platform that integrates 10 data centers in Milan, Rome, Trento and Verona, the largest Italian private Internet exchange (Avalon) and a fiber-optic network of over 15,000 km along the major highways.

About Enter

Enter is a leading European network and cloud provider focused on providing connectivity, data center and internet solutions throughout Europe, the U.S. and Asia-Pacific. The company's IP backbone spans Europe's largest PoPs (Frankfurt, Amsterdam, London, Paris, Madrid, Stockholm, Brussels, Vienna, Prague and Budapest), as well as the U.S. (New York) and Far East (Hong Kong).

In 2012, the company developed Enter Cloud Suite, the first European, OpenStack- based cloud IaaS service available in Milan, Frankfurt and Amsterdam, and is one of the official cloud platforms of 52 European institutions and agencies, such as the European Parliament and Court of Justice.

MEDIA CONTACT:

Giuseppe Sammartino
External Relations IRIDEOS S.p.A. Mobile +39 335.3000.24
gsam.ext@irideos.it www.irideos.it

iMiller Public Relations for Enter
+1.866.307.2510
media@ente.eu




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IRIDEOS via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum